Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 78235, held by Zydus Pharms USA Inc. Topiramate.
As of Nov 15, 2026, ANDA 78235 (Topiramate), held by Zydus Pharms USA Inc, was first approved by FDA on Mar 27, 2009, with 23 approved supplements and 0 published complete response letters.
Topiramate is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate tablets and topiramate capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2009 | Original application | Approved | None posted |
| Topiramate25MG · tablet;oral | Topiramate | Rx |
| Topiramate50MG · tablet;oral | Topiramate | Rx |
| Topiramate100MG · tablet;oral | Topiramate | Rx |
| Topiramate200MG · tablet;oral | Topiramate | Rx |
| Oct 23, 2024 | Supplement 35Labeling · Standard review | Approved | None posted |
| Sep 8, 2023 | Supplement 34Labeling · Standard review | Approved | None posted |
| May 25, 2023 | Supplement 33Labeling · Standard review | Approved | None posted |
| May 25, 2023 | Supplement 32Labeling · Standard review | Approved | None posted |
| Jan 7, 2022 | Supplement 31Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 29Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 25Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 24Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 23Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 21Labeling · Standard review | Approved | None posted |
| Oct 1, 2020 | Supplement 20Labeling · Standard review | Approved | None posted |
| Oct 30, 2015 | Supplement 18Labeling · Standard review | Approved | None posted |
| Oct 30, 2015 | Supplement 16Labeling · Standard review | Approved | None posted |
| Oct 30, 2015 | Supplement 15Labeling · Standard review | Approved | None posted |
| Nov 18, 2014 | Supplement 14Labeling · Standard review | Approved | None posted |
| Nov 18, 2014 | Supplement 12Labeling · Standard review | Approved | None posted |
| Nov 18, 2014 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 18, 2014 | Supplement 8Labeling | Approved | None posted |
| Jun 24, 2011 | Supplement 7Labeling | Approved | None posted |
| Jun 24, 2011 | Supplement 6Labeling | Approved | None posted |
| Aug 13, 2010 | Supplement 4Labeling | Approved | None posted |
| Jan 13, 2010 | Supplement 2REMS | Approved | None posted |
| Jan 13, 2010 | Supplement 1Labeling | Approved | None posted |
| Mar 27, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters